In a report released today, Tejas Savant from Morgan Stanley maintained a Buy rating on 10x Genomics (TXG - Research Report), with a price target of $64.00. The company's shares closed yesterday at $31.90.According to TipRanks, Savant is an analyst with an average return of -14.0% and a 31.76% success rate. Savant covers the Healthcare sector, focusing on stocks such as Hologic, Thermo Fisher, and Catalent.Currently, the analyst consensus on 10x Genomics is a Moderate Buy with an average price target of $54.33, a 70.31% upside from current levels. In a report released yesterday, Cowen & Co. also maintained a Buy rating on the stock with a $52.00 price target.
https://www.tipranks.com/news/blurbs/10x-genomics-txg-gets-a-buy-from-morgan-stanley?utm_source=advfn.com&utm_medium=referral
10x Genomics (NASDAQ:TXG)
Historical Stock Chart
From Jan 2023 to Feb 2023 Click Here for more 10x Genomics Charts.
10x Genomics (NASDAQ:TXG)
Historical Stock Chart
From Feb 2022 to Feb 2023 Click Here for more 10x Genomics Charts.